Biohaven secures up to $795 million partnership with SK Biopharma for global epilepsy drug rights

Biohaven announced a commercial partnership for its late-stage epilepsy program. South Korea-based SK Biopharma has agreed to pay up to $795 million for worldwide rights to the company's Kv7 ion channel platform, which includes its lead candidate.

The deal gives Biohaven a significant upfront payment and potential milestones, while SK Biopharma will handle development and commercialization outside the United States. Both companies expect the collaboration to accelerate the drug's path to market.

The agreement highlights growing interest in novel ion-channel therapies for epilepsy and expands Biohaven's reach into Asian markets.